Market Overview

Align Tech Faces Slowing Growth, Potential Headwinds, Morgan Stanley Says In Downgrade

Align Tech Faces Slowing Growth, Potential Headwinds, Morgan Stanley Says In Downgrade

Orthodontic supplier Align Technology, Inc. (NASDAQ: ALGN)'s long-term potential is likely to be overshadowed by slowing growth in the near term and a "demanding" multiple, according to Morgan Stanley. 

The Analyst

Analyst Steve Beuchaw downgraded shares of Align Technology from Overweight to Equal-weight and reduced the price target from $300 to $270.

The Thesis

Align Technology's core Invisalign volume has accelerated by over 1,000 basis points to 30-plus-percent since the end of 2016, taking multiples 70 percent higher, Beuchaw said in a Wednesday note.

The company is a long-term attractive opportunity, with "world-class" execution and a 12-million-plus total addressable market in clear aligner orthodontics, the analyst said. 

Slowing growth in 2018 could drive a multiple de-rating from Align's current 50-percent premium to its historical relationship with the S&P, Beuchaw said. 

Align's headwinds include the following, Beuchaw said: a flattening of U.S. high-end U.S. consumer confidence, the loss of Align's supply arrangement with SmileDirectClub, an uptake of the one-week aligner change-out schedule that is likely to be less incremental, competitive announcements, a mix shift toward non-comprehensive cases and a rising interest rate scenario.

Morgan Stanley lowered its 2020 revenue and earnings per share estimates for Align, citing the potential loss of the SDC supply contract in 2020 and the pushing out of a more automated general practitioner aligner solution to the second half of this year.

The Price Action

Shares of Align Technology have added about 25 percent year-to-date.

The stock was plunging 7.82 percent at the time of publication Thursday.

Related Links:

Henry Schein, Patterson Companies Downgraded On Amazon Fears

Danaher Was Just Added To An Important JP Morgan List; Here's Why

Latest Ratings for ALGN

Nov 2019MaintainsBuy
Oct 2019MaintainsOverweight
Jul 2019MaintainsOutperform

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Steve BeuchawAnalyst Color Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Related Articles (ALGN)

View Comments and Join the Discussion!

Latest Ratings

VRTXCantor FitzgeraldMaintains229.0
HCMCLSAInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Day Market Update: Sears Hometown and Outlet Stores Falls Following Q4 Results; Bio-Path Shares Surge

Once Sync Limited Looks To Make Financial Frontrunners Out Of Africa's Unbanked